Preparing amorphous hydrophobic drug nanoparticles by nanoporous membrane extrusion

Nanomedicine

Volumn 8, Issue 3, 2013, Pages 333-341

  Guo, Peng ^a,b,c   Hsu, Tammy M ^a   Zhao, Yaping ^a,d   Martin, Charles R ^b   Zare, Richard N ^a  

^a STANFORD UNIVERSITY   (United States)

^b University of Florida   (United States)

^c HARVARD UNIVERSITY   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

butylated hydroxytoluene; hydrophobic drug; nanoparticle; nanoporous membrane extrusion; silymarin; U tube; carotene

Indexed keywords

BETA CAROTENE; BUTYLCRESOL; NANOPARTICLE; SILYMARIN;

ARTICLE; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; HYDROPHOBICITY; MEMBRANE; MORPHOLOGY; NANOPORE; NANOPOROUS MEMBRANE EXTRUSION; PRECIPITATION; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

EID: 84874833962     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.119     Document Type: Article

References (40)

1. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44(1), 235-249 (2000)
2. Cooper ER. Nanoparticles: a personal experience for formulating poorly water soluble drugs. J. Control. Release 141(3), 300-302 (2010)
3. Gao L, Zhang D, Chen M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanopart. Res. 10(5), 845-862 (2008)
4. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189-207 (2001)
5. Gradishar WJ. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23(31), 7794-7803 (2005)
6. Baba K, Pudavar HE, Roy I et al. New method for delivering a hydrophobic drug for photodynamic therapy using pure nanocrystal form of the drug. Mol. Pharm. 4(2), 289-297 (2007)
7. Peters K, Leitzke S, Diederichs JE et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother. 45(1), 77-83 (2000)
8. Wagner V, Dullaart A, Bock A-K, Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 24(10), 1211-1217 (2006)
9. Legrand P, Lesieur S, Bochot A et al. Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation. Int. J. Pharm. 344(1-2), 33-43 (2007)
10. Antonietti M. Polyreactions in miniemulsions. Prog. Polym. Sci. 27(4), 689-757 (2002)
11. Tokumitsu H, Ichikawa H, Fukumori Y. Chitosan-gadopentetic acid complex nanoparticles for gadolinium neutron-capture therapy of cancer: preparation by novel emulsion-droplet coalescence technique and characterization. Pharm. Res. 16(12), 1830-1835 (1999)
12. Jacobson GB, Shinde R, Contag CH, Zare RN. Sustained release of drugs dispersed in polymer nanoparticles. Angew. Chem. Int. Ed. 47(41), 7880-7882 (2008)
13. Jacobson GB, Gonzalez-Gonzalez E, Spitler R et al. Biodegradable nanoparticles with sustained release of functional siRNA in skin. J. Pharm. Sci. 99(10), 4261-4266 (2010)
14. Jacobson GB, Shinde R, McCullough RL et al. Nanoparticle formation of organic compounds with retained biological activity. J. Pharm. Sci. 99(6), 2750-2755 (2010)
15. Guo P, Martin CR, Zhao Y, Ge J, Zare RN. General method for producing organic nanoparticles using nanoporous membranes. Nano Lett. 10(6), 2202-2206 (2010)
16. Ge J, Jacobson GB, Lobovkina T, Holmberg K, Zare RN. Sustained release of nucleic acids from polymeric nanoparticles using microemulsion precipitation in supercritical carbon dioxide. Chem. Commun. (Camb.) 46(47), 9034-9036 (2010)
17. Buyukserin F, Medley CD, Mota MO et al. Antibody-functionalized nano test tubes target breast cancer cells. Nanomedicine (Lond.) 3(3), 283-292 (2008)
18. Buyukserin F, Kang M, Martin CR. Plasma-etched nanopore polymer films and their use as templates to prepare "nano test tubes." Small 3(1), 106-110 (2007)
19. Hillebrenner H, Buyukserin F, Stewart JD, Martin CR. Template synthesized nanotubes for biomedical delivery applications. Nanomedicine 1(1), 39-50 (2006)
20. Hillebrenner H, Buyukserin F, Kang M, Mota MO, Stewart JD, Martin CR. Corking nano test tubes by chemical self-assembly. J. Am. Chem. Soc. 128(13), 4236-4237 (2006)
21. Maas M, Guo P, Keeney M et al. Preparation of mineralized nanofibers: collagen fibrils containing calcium phosphate. Nano Lett. 11(3), 1383-1388 (2011)
22. Liversidge G. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125(1), 91-97 (1995)
23. Müller R. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int. J. Pharm. 160(2), 229-237 (1998)
24. Panyam J. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55(3), 329-347 (2003)
25. Farokhzad OC. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103(16), 6315-6320 (2006)
26. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86(1), 1-12 (1997)
27. Sun N, Zhang X, Lu Y, Wu W. In vitro evaluation and pharmacokinetics in dogs of solid dispersion pellets containing Silybum marianum extract prepared by fluid-bed coating. Planta Med. 74(2), 126-132 (2008)
28. Wang Y, Zhang D, Liu Z et al. In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnology 21(15), 155104 (2010)
29. Rabinow BE. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3(9), 785-796 (2004)
30. You J-O, Almeda D, Ye GJ, Auguste DT. Bioresponsive matrices in drug delivery. J. Biol. Eng. 4(1), 15 (2010)
31. Ferenci P, Dragosics B, Dittrich H et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J. Hepatol. 9(1), 105-113 (1989)
32. Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334(18), 1150-1155 (1996)
33. Burton G, Ingold K. beta-Carotene: an unusual type of lipid antioxidant. Science 224(4649), 569-573 (1984)
34. Branen AL. Toxicology and biochemistry of butylated hydroxyanisole and butylated hydroxytoluene. J. Am. Oil Chem. Soc. 52(2), 59-63 (1975)
35. Yinwin K, Feng S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26(15), 2713-2722 (2005)
36. Chithrani BD, Ghazani AA, Chan WCW. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6(4), 662-668 (2006)
37. Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47(1), 3-19 (2001)
38. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53(2), 283-318 (2001)
39. Wong J, Brugger A, Khare A et al. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv. Drug Deliv. Rev. 60(8), 939-954 (2008)
40. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26(18), 3995-4021 (2005)